Please use this identifier to cite or link to this item:
Title: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Authors: Troya, Jesús
Ryan, Pablo
Ribera, Esteban
Podzamczer, Daniel
Hontañón, Victor
Terrón, Jose Alberto
Boix, Vicente
Moreno, Santiago
Barrufet, Pilar
Castaño, Manuel
Carrero, Ana
Galindo, María José
Suárez-Lozano, Ignacio
Knobel, Hernando
Raffo, Miguel
Solís, Javier
Yllescas, María
Esteban, Herminia
González-García, Juan
Berenguer, Juan
Imaz, Arkaitz
GESIDA-8314 Study Group
metadata.dc.subject.mesh: Adult
Anti-HIV Agents
CD4 Lymphocyte Count
Drug Administration Schedule
Drug Combinations
Drug Therapy, Combination
Glomerular Filtration Rate
HIV Infections
Middle Aged
RNA, Viral
Retrospective Studies
Treatment Outcome
Issue Date: 11-Oct-2016
Abstract: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. We performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA Of the 205 patients included, 75.6% were men and the median age was 49. At baseline, before switching to ABC/3TC+RPV, median time since HIV diagnosis was 13.1 years, median time with undetectable HIV-1 RNA was 6.2 years and median time of previous antiretroviral regimen was 3.1 years (48.3% patients were taking efavirenz and ABC/3TC was the most frequent backbone coformulation in 69.7% of patients). The main reasons for switching were drug toxicity/poor tolerability (60.5%) and simplification (20%). At week 48, the primary objective was achieved by 187 out of 205 (91.2%) patients by ITT analysis, and 187 out of 192 (97.4%) patients by OT analysis. The CD4+ lymphocyte count and CD4+ percentage increased significantly from baseline to week 48 by a median of 48 cells/μL (-50 to 189) and 1.2% (-1.3% to 4.1%), respectively, P The results of this study confirms that ABC/3TC+RPV is an effective, safe, and cost-effective option for the treatment of patients with virologically stable HIV-1 infection.
metadata.dc.identifier.doi: 10.1371/journal.pone.0164455
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5058546.pdf1,7 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons